Pulse Biosciences (PLSE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
11 May, 2026Executive summary
The annual meeting will be held virtually on June 11, 2026, with voting on director elections and auditor ratification.
Seven directors are nominated for election to serve until the 2027 annual meeting.
Deloitte & Touche LLP is proposed for ratification as the independent auditor for fiscal year 2026.
Stockholders of record as of April 28, 2026, are eligible to vote, with multiple voting methods available.
The Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposal 1: Election of seven directors by plurality vote.
Proposal 2: Ratification of Deloitte & Touche LLP as independent auditor for 2026, requiring majority approval.
Shareholders may submit proposals for the 2027 meeting by January 11, 2027, following specific bylaw procedures.
No cumulative voting is permitted; each share equals one vote.
Board of directors and corporate governance
The Board separates the roles of CEO and Co-Chairmen for effective oversight.
Five of seven directors are independent under Nasdaq rules.
Committees include Audit, Compensation, Nominating and Corporate Governance, and Strategic Advisory.
Directors are evaluated on ethics, experience, independence, and diversity.
A code of business conduct and an amended insider trading policy are in place.
Latest events from Pulse Biosciences
- Accelerated clinical trial progress, strong data, and a net loss of $18.6M in Q1 2026.PLSE
Q1 20268 May 2026 - Nano-pulse ablation shows 90% 12-month arrhythmia freedom and targets billion-dollar markets.PLSE
Corporate presentation16 Apr 2026 - Proprietary nsPFA tech aims to transform AFib ablation with rapid, efficient single-catheter procedures.PLSE
25th Annual Needham Virtual Healthcare Conference16 Apr 2026 - High PVI success, safety, and efficiency shown; pivotal IDE trial to expand evaluation.PLSE
Pulse Biosciences AF Symposium 2026 Analyst Event13 Apr 2026 - Advanced pivotal clinical programs and achieved revenue growth with strong clinical results.PLSE
Q4 202512 Apr 2026 - Nanosecond PFA shows unprecedented efficacy, fueling rapid IDE enrollment and strategic focus.PLSE
Oppenheimer 36th Annual Healthcare MedTech & Services Conference18 Mar 2026 - Patented nsPFA technology drives rapid clinical progress and targets multi-billion-dollar markets.PLSE
Corporate presentation18 Mar 2026 - Unprecedented AFib ablation outcomes and rapid workflow drive strong clinical and market momentum.PLSE
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Flexible $200M shelf registration supports growth in medical ablation and healthcare markets.PLSE
Registration Filing19 Feb 2026